(Q37841264)

24 August 2017

1 reference

title

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis (English)

1 reference

24 August 2017

3

Val G Hemming

1 reference

24 August 2017

Jessie R Groothuis

1

1 reference

24 August 2017

J Michael Hoopes

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

4 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

28

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

110-125

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-010-0101-y

24 August 2017

exact match

0 references

cites work

Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory syncytial virus: the virus, the disease and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Palivizumab use in very premature infants in the neonatal intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Respiratory syncytial virus infection in Navajo and White Mountain Apache children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0101-Y

10.1007/S12325-010-0101-Y

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference